Faron Pharmaceuticals
Logotype for Faron Pharmaceuticals

Faron Pharmaceuticals (FARN) investor relations material

Faron Pharmaceuticals R&D Day 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Faron Pharmaceuticals
R&D Day 2026 summary8 Oct, 2026

Pipeline overview and program updates

  • BEXERA, a randomized Phase IIb study in first-line high-risk MDS, was moving into site activation; BEXMAB enrollment was closed and follow-up continued.

  • BLAZE combines bexmarilimab with nivolumab in PD-1-refractory metastatic NSCLC and melanoma; two patients had started treatment, with first results expected in H2 2027.

  • BEXAR combines bexmarilimab with first-line doxorubicin in soft-tissue sarcoma; its first cohort was full and the second opened, with results targeted for 2027.

  • Additional investigator-led studies include bexmarilimab plus oral decitabine/cedazuridine in r/r MDS and a post-transplant MRD-positive AML study; protocols were being finalized or submitted.

  • Management expected data during 2027 from four, potentially five, indications; further investigator-led proposals exceeded current sponsorship capacity.

Clinical trial data and development milestones

  • Frontline BEXMAB showed 45% CR by IWG 2006 and 41% CR+CReq by IWG 2023; median CR duration was 16.1 months, 57% of transfusion-dependent patients became independent, and 67% of CR patients were MRD-negative.

  • In 33 r/r MDS patients, BEXMAB showed 64% overall response, 12% CR+PR, 18% bridged to transplant and estimated median OS of 14.5 months; its small, single-arm design limits comparative conclusions.

  • BEXERA is a randomized, double-blind, placebo-controlled Phase 2b in ~90 treatment-naïve HR-MDS patients, comparing bexmarilimab 1 or 3 mg/kg plus azacitidine with placebo plus azacitidine; primary objectives include dose selection and CR+CR-equivalent.

  • BEXERA was planned across 35 U.S., European and U.K. sites; first treatment was expected in Q4 2026, with dose selection and a readout targeted for 2027.

  • MATINS showed 25%–35% benefit in some solid-tumor cohorts; CLEVER-1-positive macrophages emerged as a candidate response biomarker requiring validation in BEXERA and BLAZE.

R&D strategy and innovation priorities

  • Bexmarilimab binds CLEVER-1 to reprogram immunosuppressive myeloid cells, increase antigen presentation and effector T-cell activity, and make azacitidine-resistant blast cells more sensitive.

  • Patient and bone-marrow analyses indicated immune and hematopoietic reprogramming, reduced suppressive monocyte-lineage cells, progenitor activation, increased lymphocyte abundance and function, and greater target engagement in patients achieving CR.

  • BEXERA incorporates lessons from prior HMA-combination failures, including realistic effect assumptions, placebo control, stratification by TP53, blast percentage and IPSS-M, dose comparison, and adaptive sample-size planning.

  • Development prioritizes HR-MDS through Phase 2b and Phase 3, alongside phased proof-of-concept studies in solid and hematologic tumors, including sarcoma and PD-1-refractory melanoma and lung cancer.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Faron Pharmaceuticals earnings date

Logotype for Faron Pharmaceuticals
H2 20263 Mar, 2027
Faron Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Faron Pharmaceuticals earnings date

Logotype for Faron Pharmaceuticals
H2 20263 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Faron Pharmaceuticals is a Finland-based clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and other serious conditions. The company’s research targets immune system modulation to treat aggressive diseases with unmet medical needs. Faron Pharmaceuticals is headquartered in Turku, Finland, and its shares are listed on the AIM.